Recent evidence indicates inhibiting GPX4 expression in LAR subtype breast cancer induces ferroptosis in cancer cells and significantly increases the amounts of various T cell subtypes, including CD4+ and CD8+ T cells, switching the TME from "cold" to "hot" 35. Here, CD8A is linked to breast cancer.